Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Tracey Weiss,1 Richard D Carr,2,3 Sampriti Pal,4 Lingfeng Yang,1 Baanie Sawhney,4 Robert Boggs,1 Swapnil Rajpathak,1 Kristy Iglay1 1Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, NJ, 07033, USA; 2Global Medical Affairs, Merck Sharp & Dohme Limited (MS...
Main Authors: | Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, Rajpathak S, Iglay K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-11-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-adherence-and-discontinuation-of-glucagon-like-peptide-1-re-peer-reviewed-article-PPA |
Similar Items
-
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
by: Lingfeng Yang, et al.
Published: (2022-01-01) -
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
by: Lisan Ji, et al.
Published: (2024-09-01) -
Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01) -
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01) -
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)